Agil 100 EC

Primær information

  • Handelsnavn:
  • Agil 100 EC Emulsionskoncentrat
  • Lægemiddelform:
  • Emulsionskoncentrat
  • Sammensætning:
  • 100 g/l propaquizafop
  • Brugt til:
  • Planter
  • Medicin typen:
  • agrokemiske

Dokumenter

  • for den brede offentlighed:
  • Oplysningerne indlægssedlen for dette produkt er i øjeblikket ikke tilgængelig, kan du sende en anmodning til vores kundeservice, og vi vil give dig besked, så snart vi er i stand til at opnå det.


    Anmode informationsbrochure for offentligheden.

  • for sundhedspersonale:
  • Oplysningerne indlægssedlen for dette produkt er i øjeblikket ikke tilgængelig, kan du sende en anmodning til vores kundeservice, og vi vil give dig besked, så snart vi er i stand til at opnå det.


    Anmode informationsbrochure for sundhedspersonale.

Lokation

  • Fås i:
  • Agil 100 EC Emulsionskoncentrat
    Danmark
  • Sprog:
  • dansk

Andre oplysninger

Status

  • Kilde:
  • SEGES Landbrug & Fødevarer
  • Autorisation status:
  • Markedsført
  • Autorisationsnummer:
  • 396-12
  • Sidste ændring:
  • 07-02-2018
  • Oplysningerne indlægssedlen for dette produkt er i øjeblikket ikke tilgængelig, kan du sende en anmodning til vores kundeservice, og vi vil give dig besked, så snart vi er i stand til at opnå det.

    Anmode informationsbrochure for offentligheden.

20-4-2018

Pending EC decision:  Credelio, lotilaner, Opinion date: 19-Apr-2018

Pending EC decision: Credelio, lotilaner, Opinion date: 19-Apr-2018

Europe - EMA - European Medicines Agency

20-4-2018

Pending EC decision:  Alsitek, masitinib, Opinion date: 18-Apr-2018

Pending EC decision: Alsitek, masitinib, Opinion date: 18-Apr-2018

Europe - EMA - European Medicines Agency

9-4-2018

Club 13 Recalls Kratom Maeng Da Red Powder and Capsules Because of Possible Health Risk

Club 13 Recalls Kratom Maeng Da Red Powder and Capsules Because of Possible Health Risk

Club 13 of St. Augustine, FL is recalling 15-gram, 30-gram, 90-gram, 150-gram, and 454-gram pouches, and all bulk orders of "Maeng Da Red" kratom powder; and 5-count, 25-count, 50-count, 100-count, 120-count capsule, and all bulk capsule orders of “Maeng Da Red” kratom bottles; and 5-count, 20-count, 25-count, 40-count, 50-count capsule “Maeng Da Red XS” kratom bottles because they have the potential to be contaminated with Salmonella , an organism which can cause serious and sometimes fatal infections i...

FDA - U.S. Food and Drug Administration

23-3-2018

Pending EC decision:  Cabometyx , cabozantinib, Opinion date: 22-Mar-2018

Pending EC decision: Cabometyx , cabozantinib, Opinion date: 22-Mar-2018

Europe - EMA - European Medicines Agency

23-3-2018

Pending EC decision:  Prasugrel Mylan, prasugrel, Opinion date: 22-Mar-2018

Pending EC decision: Prasugrel Mylan, prasugrel, Opinion date: 22-Mar-2018

Europe - EMA - European Medicines Agency

23-3-2018

Pending EC decision:  Repatha, evolocumab, Opinion date: 22-Mar-2018

Pending EC decision: Repatha, evolocumab, Opinion date: 22-Mar-2018

Europe - EMA - European Medicines Agency

23-3-2018

Pending EC decision:  Dexxience, betrixaban, Opinion date: 22-Mar-2018

Pending EC decision: Dexxience, betrixaban, Opinion date: 22-Mar-2018

Europe - EMA - European Medicines Agency

23-3-2018

Pending EC decision:  Rubraca, rucaparib, Opinion date: 22-Mar-2018

Pending EC decision: Rubraca, rucaparib, Opinion date: 22-Mar-2018

Europe - EMA - European Medicines Agency

23-3-2018

Pending EC decision:  Pemetrexed Krka, pemetrexed, Opinion date: 22-Mar-2018

Pending EC decision: Pemetrexed Krka, pemetrexed, Opinion date: 22-Mar-2018

Europe - EMA - European Medicines Agency

23-3-2018

Pending EC decision:  Timloze, abaloparatide, Opinion date: 22-Mar-2018

Pending EC decision: Timloze, abaloparatide, Opinion date: 22-Mar-2018

Europe - EMA - European Medicines Agency

23-3-2018

Pending EC decision:  Zessly, infliximab, Opinion date: 22-Mar-2018

Pending EC decision: Zessly, infliximab, Opinion date: 22-Mar-2018

Europe - EMA - European Medicines Agency

23-3-2018

Pending EC decision:  Kanjinti, trastuzumab, Opinion date: 22-Mar-2018

Pending EC decision: Kanjinti, trastuzumab, Opinion date: 22-Mar-2018

Europe - EMA - European Medicines Agency

23-3-2018

Pending EC decision:  Ivemend, fosaprepitant, Opinion date: 22-Mar-2018

Pending EC decision: Ivemend, fosaprepitant, Opinion date: 22-Mar-2018

Europe - EMA - European Medicines Agency

23-3-2018

Pending EC decision:  Eladynos, abaloparatide, Opinion date: 22-Mar-2018

Pending EC decision: Eladynos, abaloparatide, Opinion date: 22-Mar-2018

Europe - EMA - European Medicines Agency

16-3-2018

Pending EC decision:  Onsior, robenacoxib, Opinion date: 15-Mar-2018

Pending EC decision: Onsior, robenacoxib, Opinion date: 15-Mar-2018

Europe - EMA - European Medicines Agency

16-3-2018

Pending EC decision:  Semintra, telmisartan, Opinion date: 15-Mar-2018

Pending EC decision: Semintra, telmisartan, Opinion date: 15-Mar-2018

Europe - EMA - European Medicines Agency

28-2-2018

Help 100% & Pure Natural & Body Slim capsules

Help 100% & Pure Natural & Body Slim capsules

Help 100% & Pure Natural & Body Slim Capsules pose a serious risk to your health and should not be taken

Therapeutic Goods Administration - Australia

23-2-2018

Hospira Issues A Voluntary Nationwide Recall For Labetalol Hydrochloride Injection, USP, Due To The Potential Of Cracked Glass At The Rim Surface Of The Vials

Hospira Issues A Voluntary Nationwide Recall For Labetalol Hydrochloride Injection, USP, Due To The Potential Of Cracked Glass At The Rim Surface Of The Vials

Hospira, Inc., a Pfizer company, is voluntarily recalling 3 lots of Labetalol Hydrochloride Injection, USP, 100 mg/20 mL Vial (NDC 0409-2267-20), and one lot of Labetalol Hydrochloride Injection, USP, Novaplus® (NDC 0409-2267-25) to the hospital/institution level. Hospira, Inc. initiated this recall due to the discovery of cracks on the rim surface of vials for these lots, which is covered by the stopper and crimp seal.

FDA - U.S. Food and Drug Administration

23-2-2018

Pending EC decision:  Alpivab, peramivir, Opinion date: 22-Feb-2018

Pending EC decision: Alpivab, peramivir, Opinion date: 22-Feb-2018

Europe - EMA - European Medicines Agency

23-2-2018

Pending EC decision:  Kineret, anakinra, Opinion date: 22-Feb-2018

Pending EC decision: Kineret, anakinra, Opinion date: 22-Feb-2018

Europe - EMA - European Medicines Agency

23-2-2018

Pending EC decision:  Isentress, raltegravir, Opinion date: 22-Feb-2018

Pending EC decision: Isentress, raltegravir, Opinion date: 22-Feb-2018

Europe - EMA - European Medicines Agency

23-2-2018

Pending EC decision:  Xgeva, denosumab, Opinion date: 22-Feb-2018

Pending EC decision: Xgeva, denosumab, Opinion date: 22-Feb-2018

Europe - EMA - European Medicines Agency

23-2-2018

Pending EC decision:  Mylotarg, gemtuzumab ozogamicin, Opinion date: 22-Feb-2018

Pending EC decision: Mylotarg, gemtuzumab ozogamicin, Opinion date: 22-Feb-2018

Europe - EMA - European Medicines Agency

23-2-2018

Pending EC decision:  Sutent, sunitinib, Opinion date: 22-Feb-2018

Pending EC decision: Sutent, sunitinib, Opinion date: 22-Feb-2018

Europe - EMA - European Medicines Agency

23-2-2018

Pending EC decision:  Nerlynx, neratinib, Opinion date: 22-Feb-2018

Pending EC decision: Nerlynx, neratinib, Opinion date: 22-Feb-2018

Europe - EMA - European Medicines Agency

23-2-2018

Pending EC decision:  Feraccru, ferric maltol, Opinion date: 22-Feb-2018

Pending EC decision: Feraccru, ferric maltol, Opinion date: 22-Feb-2018

Europe - EMA - European Medicines Agency

23-2-2018

Pending EC decision:  Amglidia, glibenclamide, Opinion date: 22-Feb-2018

Pending EC decision: Amglidia, glibenclamide, Opinion date: 22-Feb-2018

Europe - EMA - European Medicines Agency

23-2-2018

Pending EC decision:  Bosulif, bosutinib, Opinion date: 22-Feb-2018

Pending EC decision: Bosulif, bosutinib, Opinion date: 22-Feb-2018

Europe - EMA - European Medicines Agency

23-2-2018

Pending EC decision:  Lynparza, olaparib, Opinion date: 22-Feb-2018

Pending EC decision: Lynparza, olaparib, Opinion date: 22-Feb-2018

Europe - EMA - European Medicines Agency

21-2-2018

Sugar in food

Sugar in food

Glucose, galactose, fructose, sucrose, lactose, maltose… these are all types of what is commonly called sugar. Given the health effects that can be caused by excessive sugar consumption, ANSES recommends not consuming more than 100 g of sugar per day (excluding lactose and galactose) and not more than one sweetened beverage. Language English

France - Agence Nationale du Médicament Vétérinaire

16-2-2018

Pending EC decision:  Metacam, meloxicam, Opinion date: 15-Feb-2018

Pending EC decision: Metacam, meloxicam, Opinion date: 15-Feb-2018

Europe - EMA - European Medicines Agency

16-2-2018

Pending EC decision:  Clevor, ropinirole, Opinion date: 15-Feb-2018

Pending EC decision: Clevor, ropinirole, Opinion date: 15-Feb-2018

Europe - EMA - European Medicines Agency

18-4-2018

Love Your Hair Color? You Have Over 100 Genes to Thank.

Love Your Hair Color? You Have Over 100 Genes to Thank.

Title: Love Your Hair Color? You Have Over 100 Genes to Thank.Category: Health NewsCreated: 4/16/2018 12:00:00 AMLast Editorial Review: 4/17/2018 12:00:00 AM

US - MedicineNet

3-4-2018

BRILLIA (Lapine S-100 Immune Globulin 12 Hpc, 30 Hpc, 50 Hpc) Pill [Hadaf LLC]

BRILLIA (Lapine S-100 Immune Globulin 12 Hpc, 30 Hpc, 50 Hpc) Pill [Hadaf LLC]

Updated Date: Apr 3, 2018 EST

US - DailyMed

25-3-2018

The TGA statement in relation to ABC’s Fact Check article on deaths from OTC codeine

The TGA statement in relation to ABC’s Fact Check article on deaths from OTC codeine

In reference to the ABC’s Fact Check article “Will the move to make codeine prescription-only save a 100 lives a year” the Therapeutic Goods Administration (TGA) would like to clarify:

Therapeutic Goods Administration - Australia

20-3-2018

Avastin (Roche Registration GmbH)

Avastin (Roche Registration GmbH)

Avastin (Active substance: bevacizumab) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)1752 of Tue, 20 Mar 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/582/T/100

Europe -DG Health and Food Safety

19-3-2018

Pegasys (Roche Registration GmbH)

Pegasys (Roche Registration GmbH)

Pegasys (Active substance: peginterferon alfa-2a) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)1692 of Mon, 19 Mar 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/395/T/100

Europe -DG Health and Food Safety

16-3-2018

Scientific guideline:  Public consultation concerning a request for CVMP opinion under Article 30(3) of Regulation (EC) No 726/2004 on the risk for the consumer resulting from the use of diethanolamine as an excipient in veterinary medicinal products for

Scientific guideline: Public consultation concerning a request for CVMP opinion under Article 30(3) of Regulation (EC) No 726/2004 on the risk for the consumer resulting from the use of diethanolamine as an excipient in veterinary medicinal products for

The European Medicines Agency is seeking stakeholder input on any information or data that may help its Committee for Medicinal Products for Veterinary Use (CVMP) to reach an opinion on consumer risk from using diethanolamine as an excipient in veterinary medicines for food-producing animals.

Europe - EMA - European Medicines Agency

16-3-2018

MRL pending EC decision:  Diflubenzuron - Summary opinion of the CVMP on the establishment of maximum residue limits AA

MRL pending EC decision: Diflubenzuron - Summary opinion of the CVMP on the establishment of maximum residue limits AA

On 15 March 2018, the Committee for Medicinal Products for Veterinary Use (CVMP) adopted an opinion recommending the amendment of the entry for diflubenzuron.

Europe - EMA - European Medicines Agency

16-3-2018

MRL pending EC decision:  Isoflurane - Summary opinion of the CVMP on the establishment of maximum residue limits

MRL pending EC decision: Isoflurane - Summary opinion of the CVMP on the establishment of maximum residue limits

On 15 March 2018, the Committee for Medicinal Products for Veterinary Use (CVMP) adopted an opinion2 recommending the establishment of MRLs for isoflurane in porcine species and amending the existing entry for Equidae.

Europe - EMA - European Medicines Agency

2-3-2018

CHILDRENS IBUPROFEN 100 (Ibuprofen) Suspension [Walgreen Company]

CHILDRENS IBUPROFEN 100 (Ibuprofen) Suspension [Walgreen Company]

Updated Date: Mar 2, 2018 EST

US - DailyMed

28-2-2018

Voltaren Gel vs. Naprosyn

Voltaren Gel vs. Naprosyn

Voltaren Gel (diclofenac sodium topical gel) and Naprosyn (naproxen; other brand names: EC-Naprosyn and Anaprox/Anaprox DS) are nonsteroidal anti-inflammatory drugs (NSAIDs) used to treat osteoarthritis joint pain.

US - RxList

26-2-2018

EQUIZONE 50/100 (Pheynlbutazone) Powder [AG Pharmaceuticals]

EQUIZONE 50/100 (Pheynlbutazone) Powder [AG Pharmaceuticals]

Updated Date: Feb 26, 2018 EST

US - DailyMed

23-2-2018

TYLAN 100 (Tylosin Phosphate) Granule [Elanco US Inc.]

TYLAN 100 (Tylosin Phosphate) Granule [Elanco US Inc.]

Updated Date: Feb 23, 2018 EST

US - DailyMed

21-2-2018

BRILLIA (S-100 Protein Antibody) Pill [Hadaf LLC]

BRILLIA (S-100 Protein Antibody) Pill [Hadaf LLC]

Updated Date: Feb 21, 2018 EST

US - DailyMed